Paul Hudson, Sanofi CEO (via Getty)

Sanofi CEO Paul Hud­son con­tin­ues hunt for new tech, spear­ing a deal with organoid start­up

Sanofi is dip­ping its toes in­to a wide range of new tech­nolo­gies as CEO Paul Hud­son looks to find its next big break­through. His lat­est pick comes from an emerg­ing field that’s had plen­ty of buzz but few tan­gi­ble re­sults in drug de­vel­op­ment so far.

The French phar­ma an­nounced on Tues­day a deal with Prel­lis Bi­o­log­ics, a new biotech that claims to have de­vel­oped an organoid sys­tem in its labs that can mim­ic the hu­man im­mune sys­tem. Al­though the start­up has on­ly raised a mod­est sum by mod­ern biotech stan­dards — it an­nounced a $14.5 mil­lion Se­ries B in De­cem­ber — its tech­nol­o­gy has at­tract­ed the in­ter­est of large com­pa­nies. In Jan­u­ary, the com­pa­ny al­so an­nounced a li­cens­ing deal with Bris­tol My­ers Squibb.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.